[關(guān)鍵詞]
[摘要]
他汀類(lèi)藥物是目前臨床應(yīng)用最廣泛的降脂藥物，為心血管疾病的一級(jí)、二級(jí)預(yù)防的基石。他汀類(lèi)藥物為羥基-甲基戊二酰輔酶Ａ還原酶抑制劑，可以顯著降低血清總膽固醇、低密度脂蛋白膽固醇、三酰甘油水平，同時(shí)可輕度升高高密度脂蛋白膽固醇水平。目前研究的參與他汀類(lèi)藥物代謝的酶、轉(zhuǎn)運(yùn)蛋白、受體等基因多態(tài)性對(duì)他汀類(lèi)藥物安全性、不良反應(yīng)有重要影響。闡述遺傳因素載脂蛋白E、SLCO1B1、ATP結(jié)合盒轉(zhuǎn)運(yùn)蛋白B1、ABCG2、CYP、3-羥基-3-甲基戊二酰輔酶A還原酶基因等相關(guān)基因多態(tài)性對(duì)他汀類(lèi)藥物療效和安全性的影響，為他汀類(lèi)藥物的個(gè)體化用藥提供參考依據(jù)。
[Key word]
[Abstract]
Statins are the most widely used lipid-lowering drugs in clinical practice, and are the cornerstone of primary and secondary prevention of cardiovascular disease. Statins are hydroxymethylglutaryl coenzyme A reductase inhibitors, which can significantly reduce serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triacylglycerol (TG) levels, and slightly increase high-density lipoprotein cholesterol (HDL-C) levels. The genetic polymorphisms of enzymes, transporters, receptors and other genes involved in the metabolism of statins currently studied play an important role in safety and adverse reactions of statins. This article describes the influence of genetic factors such as ApoE gene, SLCO1B1 gene, ABCB1 gene, ABCG2 gene, CYP family gene, HMGCR gene, and other related gene polymorphisms on the efficacy and safety of statins, providing a reference for the individualized use of statins.
[中圖分類(lèi)號(hào)]
R968
[基金項(xiàng)目]
河北省醫(yī)學(xué)科學(xué)研究課題計(jì)劃項(xiàng)目（20220310）
